Santhera Pharmaceuticals Holding AG

Santhera’s Italian reimbursement win for AGAMREE and a new board hire boost DMD market access, revenue growth, and investor confidence.

Santhera’s AGAMREE gains EU age‑expansion and Italian reimbursement, unlocking a larger DMD patient base and boosting investor confidence in its neuromuscular breakthrough.

Santhera’s AGAMREE (vamorolone) matches steroid efficacy for Duchenne muscular dystrophy but cuts fractures, cataracts, and growth loss by 80‑90%, offering a safer, more effective standard therapy.

Santhera Pharmaceuticals faces steep financial hurdles yet remains committed to innovative neuromuscular and metabolic treatments, offering investors a risky yet potentially transformative biotech story.

Santhera Pharmaceuticals has partnered with Ikris Pharma Network to distribute its Duchenne Muscular Dystrophy treatment, AGAMREE, in India, marking a significant expansion of the treatment’s global availability.

Santhera Pharmaceuticals has partnered with Uniphar to distribute its treatment AGAMREE for Duchenne muscular dystrophy in the GCC region, marking a significant strategic move to expand its market presence and potentially boost its financial health.

Santhera Pharmaceuticals has partnered with Uniphar to distribute its Duchenne muscular dystrophy treatment AGAMREE in five Gulf Cooperation Council countries, starting with a named-patient program in Q1 2026.

Santhera Pharmaceuticals has expanded its global reach by signing an exclusive distribution agreement with Gen İlaç in Türkiye for its Duchenne muscular dystrophy treatment, AGAMREE.

Santhera Pharmaceuticals reported a year of transformation and growth in 2024, driven by the successful launch of AGAMREE, a groundbreaking treatment for Duchenne Muscular Dystrophy, and strategic financial management.